Plain-English translation of NCT07632339 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two new immunotherapy drugs called becotatug vedotin and pucotenlimab for patients with head and neck cancer that has come back and can be surgically removed. You would receive these medications before surgery to try to shrink the tumor, then have surgery, and then receive additional treatment afterward based on how your cancer responds. The goal is to improve survival and reduce the chance the cancer returns again.
Head and neck cancer that comes back after initial treatment is very serious—even after surgery, at least 20% of patients experience another recurrence or the cancer spreads to other parts of the body. Standard surgery alone is not enough for many patients, so this trial is testing whether starting with the new immunotherapy medications before surgery can give patients a better chance of long-term survival.
You likely qualify if…
You likely don't qualify if…
You would receive two doses of the immunotherapy medications given by infusion every three weeks before your surgery. Then, about four weeks after receiving the last dose, you would have surgery to remove the cancer. Six weeks after surgery, based on how your cancer responded to the medication and other risk factors, you would either receive six more doses of one of the medications, or receive standard post-surgery treatment. The whole study participation would take several months, with regular clinic visits for treatment and monitoring.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China